

Hallvard Holdaas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6741588/publications.pdf>

Version: 2024-02-01

72
papers

1,612
citations

516710

16
h-index

302126

39
g-index

73
all docs

73
docs citations

73
times ranked

2296
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased risk of ischaemic heart disease after kidney donation. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 928-936.	0.7	10
2	Serum markers of fibrosis, cardiovascular and all-cause mortality in hemodialysis patients: the AURORA trial. <i>Clinical Research in Cardiology</i> , 2022, 111, 614-626.	3.3	8
3	Use of Statins in Kidney Transplant Recipients in Norway. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1370.	2.6	0
4	Arteriovenous fistula thrombosis is associated with increased all-cause and cardiovascular mortality in haemodialysis patients from the AURORA trial. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 116-122.	2.9	24
5	Improved cardiovascular risk prediction in patients with end-stage renal disease on hemodialysis using machine learning modeling and circulating microribonucleic acids. <i>Theranostics</i> , 2020, 10, 8665-8676.	10.0	18
6	SO028LONG-TERM OUTCOMES IN LIVE KIDNEY DONORS: PREVALENCE OF ISCHEMIC HEART DISEASE, DIABETES, CANCER AND CEREBROVASCULAR DISEASE AFTER DONATION COMPARED TO HEALTHY CONTROLS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
7	Predicting donor, recipient and graft survival in living donor kidney transplantation to inform pretransplant counselling: the donor and recipient linked iPREDICTLIVING tool – a retrospective study. <i>Transplant International</i> , 2020, 33, 729-739.	1.6	9
8	Increased long-term risk for hypertension in kidney donors – a retrospective cohort study. <i>Transplant International</i> , 2020, 33, 536-543.	1.6	18
9	Exploring the potential effect of paricalcitol on markers of inflammation in de novo renal transplant recipients. <i>PLoS ONE</i> , 2020, 15, e0243759.	2.5	1
10	Title is missing!. , 2020, 15, e0243759.		0
11	Title is missing!. , 2020, 15, e0243759.		0
12	Title is missing!. , 2020, 15, e0243759.		0
13	Title is missing!. , 2020, 15, e0243759.		0
14	Long-term risk for kidney donors with hypertension at donation – a retrospective cohort study. <i>Transplant International</i> , 2019, 32, 960-964.	1.6	3
15	A Fully Automated Method for the Determination of Serum Belatacept and Its Application in a Pharmacokinetic Investigation in Renal Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 11-18.	2.0	11
16	Genetic markers associated with long-term cardiovascular outcome in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2019, 19, 1444-1451.	4.7	4
17	Regarding age-calibrated glomerular filtration rate. <i>Kidney International</i> , 2019, 95, 234-235.	5.2	1
18	High tacrolimus clearance - a risk factor for development of interstitial fibrosis and tubular atrophy in the transplanted kidney: a retrospective single-center cohort study. <i>Transplant International</i> , 2019, 32, 257-269.	1.6	16

#	ARTICLE	IF	CITATIONS
19	Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, gfw396.	0.7	6
20	Lupus nephritis: low urinary DNase I levels reflect loss of renal DNase I and may be utilized as a biomarker of disease progression. <i>Journal of Pathology: Clinical Research</i> , 2018, 4, 193-203.	3.0	16
21	Kidney allograft subclinical rejection modulates systemic inflammation measured by C-reactive protein at 1 year after transplantation. <i>Clinical Transplantation</i> , 2018, 32, e13196.	1.6	3
22	FP737LONG TERM SURVIVAL IN KIDNEY DONORS WITH PRE EXISTING HYPERTENSION. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i294-i294.	0.7	0
23	Immunosuppression Adherence in Stable Kidney Transplant Patients Converted From Immediate- to Prolonged-Release Tacrolimus in Clinical Practice: A Norwegian Study. <i>Transplantation Direct</i> , 2018, 4, e338.	1.6	11
24	Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score. <i>BMC Nephrology</i> , 2018, 19, 212.	1.8	5
25	Mid- and Long-Term Health Risks in Living Kidney Donors. <i>Annals of Internal Medicine</i> , 2018, 169, 265.	3.9	2
26	Belatacept: Where the BENEFITS Outweigh the Risk. <i>American Journal of Kidney Diseases</i> , 2017, 69, 561-563.	1.9	0
27	Regarding "Obesity increases the risk of end-stage renal disease among living kidney donors" <i>Kidney International</i> , 2017, 91, 1256.	5.2	1
28	Long term risk of mortality after living kidney donation. <i>BMJ: British Medical Journal</i> , 2017, 357, j1770.	2.3	2
29	Early introduction of oral paricalcitol in renal transplant recipients. An open-label randomized study. <i>Transplant International</i> , 2017, 30, 827-840.	1.6	16
30	Cardiovascular Parameters to 2 years After Kidney Transplantation Following Early Switch to Everolimus Without Calcineurin Inhibitor Therapy. <i>Transplantation</i> , 2017, 101, 2612-2620.	1.0	23
31	Long-term Change in the Risk of Skin Cancer After Organ Transplantation. <i>JAMA Dermatology</i> , 2017, 153, 1270.	4.1	74
32	Tacrolimus and mycophenolate regimen and subclinical tubulo-interstitial inflammation in low immunological risk renal transplants. <i>Transplant International</i> , 2017, 30, 1119-1131.	1.6	10
33	Should patients older than 65 years be offered a second kidney transplant?. <i>BMC Nephrology</i> , 2017, 18, 13.	1.8	12
34	Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update. <i>Journal of Transplantation</i> , 2016, 2016, 1-11.	0.5	43
35	Total inflammation in early protocol kidney graft biopsies does not predict progression of fibrosis at one year post-transplant. <i>Clinical Transplantation</i> , 2016, 30, 802-809.	1.6	7
36	Low-dose tacrolimus in de novo standard risk renal transplant recipients: A single-centre experience. <i>Nephrology</i> , 2016, 21, 821-827.	1.6	7

#	ARTICLE	IF	CITATIONS
37	Regarding long-term outcome after kidney donation. <i>Transplant International</i> , 2016, 29, 381-381.	1.6	0
38	Predictors of atherosclerotic events in patients on haemodialysis: post hoc analyses from the AURORA study. <i>Nephrology Dialysis Transplantation</i> , 2016, 33, gfw360.	0.7	14
39	Long-term cardiovascular outcomes in type 1 diabetic patients after simultaneous pancreas and kidney transplantation compared with living donor kidney transplantation. <i>Diabetologia</i> , 2016, 59, 844-852.	6.3	35
40	Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients – a three-year serial echocardiographic substudy of the randomized controlled CENTRAL trial. <i>Clinical Transplantation</i> , 2015, 29, 678-684.	1.6	17
41	mTOR inhibitors and dyslipidemia in transplant recipients: A cause for concern?. <i>Transplantation Reviews</i> , 2015, 29, 93-102.	2.9	47
42	Impact of Living Kidney Donation on Long-Term Renal and Patient Survival: An Evolving Paradigm. <i>Current Transplantation Reports</i> , 2015, 2, 22-28.	2.0	1
43	Arterial haemodynamics and coronary artery calcification in adult patients with juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1515-1521.	0.9	25
44	The Authors Reply. <i>Kidney International</i> , 2015, 87, 660.	5.2	1
45	The Authors Reply. <i>Kidney International</i> , 2014, 85, 1241-1242.	5.2	2
46	The Authors Reply. <i>Kidney International</i> , 2014, 86, 447.	5.2	2
47	BP Targets in Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1371-1373.	6.1	3
48	Kidney donors and kidney transplants have abnormal aminothioliol redox status, and are at increased risk of oxidative stress and reduced redox buffer capacity. <i>Clinical Biochemistry</i> , 2014, 47, 378-382.	1.9	6
49	Neopterin is associated with cardiovascular events and all-cause mortality in renal transplant patients. <i>Clinical Transplantation</i> , 2014, 28, 111-119.	1.6	10
50	Long-term risks for kidney donors. <i>Kidney International</i> , 2014, 86, 162-167.	5.2	643
51	A drug safety evaluation of everolimus in kidney transplantation. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 1013-1022.	2.4	19
52	Conversion of Long-Term Kidney Transplant Recipients From Calcineurin Inhibitor Therapy to Everolimus: A Randomized, Multicenter, 24-Month Study. <i>Transplantation</i> , 2011, 92, 410-418.	1.0	121
53	Rosuvastatin in Diabetic Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 1335-1341.	6.1	105
54	The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: A pooled analysis of double-blind, randomized trials. <i>International Journal of Cardiology</i> , 2007, 117, 64-74.	1.7	33

#	ARTICLE	IF	CITATIONS
55	Fluvastatin may be similarly effective in older and younger people. Evidence-based Cardiovascular Medicine, 2006, 10, 11-12.	0.0	0
56	The Renal Safety Profile of Fluvastatin: Results of a Pooled Analysis. Renal Failure, 2006, 28, 487-492.	2.1	4
57	Preventing Cardiovascular Outcome in Patients with Renal Impairment. American Journal of Cardiovascular Drugs, 2005, 5, 255-269.	2.2	8
58	Haemodynamic conditions for renal PGE ₂ and renin release during α - and β -adrenergic stimulation in dogs. Acta Physiologica Scandinavica, 1985, 124, 163-172.	2.2	7
59	Evidence for bicarbonate-dependent lithium reabsorption in dog kidneys. Acta Physiologica Scandinavica, 1984, 120, 257-264.	2.2	10
60	Relationship between PGE ₂ and renin release in dog kidneys Effects of afferent arteriolar dilation and adrenergic stimulation. Acta Physiologica Scandinavica, 1984, 121, 261-268.	2.2	16
61	Glomerular filtraton rate and P _{CO2} as determinants of lithium reabsorption. Acta Physiologica Scandinavica, 1984, 121, 283-290.	2.2	6
62	Site and magnitude of the tubular inhibitory effect of expanding the extracellular volume in dogs. Acta Physiologica Scandinavica, 1984, 122, 285-298.	2.2	6
63	Ouabain inhibits renin release by a direct renal haemodynamic effect. Scandinavian Journal of Clinical and Laboratory Investigation, 1984, 44, 557-563.	1.2	3
64	Segmental distribution of vascular resistances during ureteral occlusion: The vasoconstrictive effects of angiotensin and CaCl ₂ differ from those of catecholamines and renal nerve stimulation. Acta Physiologica Scandinavica, 1983, 119, 147-158.	2.2	10
65	Conditions for stimulation of renin release by cyclic AMP in anaesthetized dogs. Scandinavian Journal of Clinical and Laboratory Investigation, 1981, 41, 535-542.	1.2	8
66	Conditions for humoral α -adrenoceptor stimulation of renin release in anaesthetized dogs. Scandinavian Journal of Clinical and Laboratory Investigation, 1981, 41, 527-534.	1.2	29
67	The role of left atrial receptors in the regulation of renin release in anesthetized dogs. Acta Physiologica Scandinavica, 1981, 111, 497-499.	2.2	5
68	Mechanism of renin release during renal nerve stimulation in dogs. Scandinavian Journal of Clinical and Laboratory Investigation, 1981, 41, 617-625.	1.2	27
69	Re-examination of the dose-response relationship for the renal effect of acetazolamide. Scandinavian Journal of Clinical and Laboratory Investigation, 1979, 39, 297-301.	1.2	12
70	To what extent does acetazolamide inhibit renal bicarbonate reabsorption?. Scandinavian Journal of Clinical and Laboratory Investigation, 1979, 39, 293-295.	1.2	2
71	Functional differences of ouabain and ethacrynic acid on renal potassium metabolism in dogs. Scandinavian Journal of Clinical and Laboratory Investigation, 1978, 38, 603-614.	1.2	14
72	Chronic Allograft Nephropathy. , 0, , 599-607.		0